Background {#Sec1}
==========

Malaria is still one of the three major infectious diseases worldwide with 216 million cases and 445,000 deaths over 100 countries in 2016 \[[@CR1]\]. Although new sustainable development goals have proposed to end malaria epidemic by 2030 \[[@CR2]\], emergence and spread of drug-resistant parasites could be a major obstacle for this achievement. *Plasmodium falciparum* parasites resistant to artemisinin-based combination therapy (ACT), the current first-line treatment for uncomplicated malaria, have already spread across the Greater Mekong sub-region \[[@CR3]\]. However, licensed anti-malarial drugs that possess similar levels of efficacy as artemisinins have not yet been obtained. Under such circumstances, an approach that rotates licensed anti-malarial drugs is suggested to be a potential strategy to combat drug-resistant parasites. Chloroquine is a candidate drug that is potentially applicable to such a strategy. This is because chloroquine-susceptible parasites have outcompeted the resistant parasites and have expanded in the absence of chloroquine selecting pressure \[[@CR4]--[@CR6]\]; subsequently, chloroquine susceptibility has been recovered several years after its discontinuance in many endemic regions, particularly in Africa \[[@CR7]--[@CR13]\]. However, a lack of this phenomenon has been also reported in some African and other endemic regions \[[@CR14]--[@CR16]\]. Therefore, the extent of this reversal across malaria-endemic countries is not fully understood \[[@CR17]\].

In Papua New Guinea, since the first report of chloroquine-resistant *P. falciparum* parasite in the 1970s \[[@CR18]\], resistant parasites have spread across the area. The clinical efficacy of chloroquine reached unacceptable levels by the mid-1990s \[[@CR19], [@CR20]\]. In 2000, a combination regimen of chloroquine or amodiaquine plus sulphadoxine--pyrimethamine was introduced as a first-line treatment for uncomplicated malaria. However, treatment failure of these regimens against *P. falciparum* reached 11--29% during 2003--2005 as assessed at day 28 \[[@CR21]\], and 15% during 2005--2007 \[[@CR22]\]. In 2010, chloroquine was completely removed from the official treatment regime and artemether plus lumefantrine was officially introduced as a first-line regimen for uncomplicated malaria. Following this discontinuance, change in the average 50% growth inhibitory concentration (IC~50~) to chloroquine was reported as 167 nM during 2005--2007 to 87 nM during 2011--2013 in the Madang Province \[[@CR23]\]. However, this IC~50~ value was still much higher than those reported in regions with reversal of chloroquine susceptibility such as Kenya (22.4 nM) \[[@CR12]\] and Senegal (34.8 nM) \[[@CR10]\]. Additionally, almost all parasites in the Madang study still harboured a chloroquine-resistant allele (K76T mutation) in the *P. falciparum* chloroquine-resistance transporter (*pfcrt*). These results indicate that a complete recovery of chloroquine susceptibility after its withdrawal has not been evidenced in Papua New Guinea and warrants further investigation. An ex vivo study was therefore performed in 2016--2018, 6--8 years after chloroquine withdrawal in Wewak district, East Sepik Province, in which the ex vivo drug susceptibility study was previously conducted during 2002--2003 \[[@CR24]\].

Methods {#Sec2}
=======

Study design and sites {#Sec3}
----------------------

Three cross-section studies for ex vivo malaria drug resistance targeted in symptomatic *P. falciparum*-infected patients were carried out at two clinics (Wirui Urban and Town) in Wewak District of East Sepik Province in Papua New Guinea. The studies began in January and ended in February in 2016 and in 2017 and from February to March in 2018. The average temperature in the studied area is 27.3 °C (min 23.8 °C, max 30.9 °C) with an annual rainfall of approximately 3000 mm. All four species of human malaria parasites were observed with limited seasonal variations between the wet (October to April) and dry (May to September) seasons and were transmitted mainly by *Anopheles farauti, Anopheles punctulatus*, and *Anopheles koliensis* \[[@CR20], [@CR25], [@CR26]\].

The Government of Papua New Guinea implemented the first country-wide free distribution of long-lasting insecticidal mosquito nets (LLIN) with financial support from the Global Fund to Fight AIDS, tuberculosis, and malaria between 2005 and 2009 (round 3 grant) and between 2009 and 2013 (round 8 grant) \[[@CR27]\]. The average LLIN usage was 55% in 2008 and 2009 \[[@CR28]\] and 32.9--67.7% during 2013--2014 \[[@CR29]\]. The mean Anopheles man biting rate was 31 bites/person/night, which is much lower than that (83 bites/person/night) observed in the pre-LLIN distribution period \[[@CR30]\]. Malaria prevalence has been considerably decreased in all endemic regions; the overall prevalence of all species was 11.1% (2008--2009), 5.1% (2010--2011), and 0.9% (2013--2014) \[[@CR29]\]. The current first-line regime includes artemether plus lumefantrine, which was officially introduced in 2010.

Ethical approvals were obtained from the Medical Research Ethical Committee of Juntendo University (No. 13-016) and the Medical Research Advisory Committee of Papua New Guinea National Department of Health (No. 14.22. & 16.41.).

Patients and blood collection {#Sec4}
-----------------------------

In both studied clinics, *P. falciparum* infection was screened using a Rapid Diagnosis Test (RDT) (CareStart™ Malaria HRP2/pLDH COMBO Test kit, Access Bio, USA) in patients (\> 1 year of age) with symptoms suspected of malaria such as axillary temperature above 37.5 °C or a fever during the previous 24 h, as reported by the family. When a *P. falciparum*-positive result was obtained, patients were enrolled after obtaining informed consent from the patients or guardians. Blood samples were obtained by finger prick (\< 2 years, 100--500 μL) or peripheral venipuncture (≥ 2 years, 1 mL) and collected into EDTA-containing tubes and immediately transferred to the central laboratories at Wewak General Hospital. Thick and thin blood smears were prepared and stained with 2% Giemsa for 30 min. Blood samples showing parasitaemia ≥ 0.05% were used for both ex vivo anti-malarial susceptibility assays and molecular analysis. Samples showing parasitaemia \< 0.05% were used for molecular analysis alone. For molecular analysis, blood samples were transferred onto chromatography filter paper (ET31CHR; Whatman Limited, Kent, UK) and separated in a plastic bag after drying at a normal temperature and stored at − 20 °C. Species-specific polymerase chain reactions (PCRs) were performed to confirm *P. falciparum* infections, as previously described \[[@CR31]\].

Ex vivo anti-malarial susceptibility assays {#Sec5}
-------------------------------------------

Ex vivo assays were performed to determine anti-malarial susceptibility to chloroquine and lumefantrine. After removing the plasma and buffy coat, erythrocyte pellets were washed thrice in complete RPMI1640 medium (Thermo Fisher Scientific Inc., Waltham, MA, USA) with 0.225 mg/mL gentamicin. Washed pellets were suspended in the 2.5% haematocrit of culture medium; RPMI-1640 containing 25 mM HEPES and 2 mM [l]{.smallcaps}-glutamine supplemented with 0.25 mg/mL gentamicin and heat-inactivated 10% serum from O blood type Japanese volunteers. Parasite density was adjusted to 0.05% with O type erythrocytes from Japanese volunteers. Next, 100 μL of parasite culture was added to each well of a 96-well culture plate, which was pre-dosed with chloroquine: 0, 25, 50, 100, 200, 400, 800, and 1600 nM or lumefantrine: 0, 1.25, 2.5, 5, 10, 20, 40, and 80 nM. The sample-applied plates were then incubated at 37 °C for 72 h in a gas atmosphere (5% CO~2~, 5% O~2~) created using the AnaeroPack^®^ malaria culture system (Mitsubishi Gas Chemical Company Inc., Tokyo, Japan). Samples were then frozen (− 20 °C overnight) and thawed until complete haemolysis was obtained. Parasite growth was assessed using an enzyme-linked immunosorbent assay (ELISA) that quantifies parasite histidine-rich protein-2 (HRP-2) as reported previously \[[@CR32]\]. The effective concentration needed to inhibit *P. falciparum* growth by 50% (IC~50~) was established by non-linear regression using an online ICEstimator software (<http://www.antimalarial-icestimator.net>) \[[@CR33]\].

Multiplicity of infections (MOIs) {#Sec6}
---------------------------------

*Plasmodium falciparum* DNA was extracted from a quarter of a blood spot (25 µL) using the QIAamp DNA blood Mini Kit (QIAGEN, Hilden, Germany). MOIs or the number of clones per sample were determined by genotyping of *merozoite surface protein 2* (*msp2*), the gene encoding the highly polymorphic locus MSP2, as reported previously \[[@CR34]\]. Briefly, a nested multiplex PCR was performed to amplify 3D7 and/or FC27 family alleles using fluorescence-labelled family-specific primers with Tks Gflex DNA Polymerase (Takara Bio Inc., Japan) in a 10-μL reaction mixture containing 1 μL of DNA template and 0.5 μM of each primer set. The nested PCR products were analysed by 2% agarose gel electrophoresis to select the samples for subsequent capillary electrophoresis analysis. Size variations of nested PCR products were analysed using an Applied Biosystems 3130/3130xl Genetic Analyzer (Life Technologies, Carlsbad, California, USA) and determined with the Peak Scanner software ver2.0 (Thermo Fisher Scientific). If minor peak heights were greater than one-third of the major peak height, these minor peaks were regarded as peaks from minor clones. Samples harbouring two or more alleles were interpreted as multiple-clonal infections.

Genotyping of *pfcrt* and *pfmdr1* {#Sec7}
----------------------------------

Polymorphisms at position 72--76 in *pfcrt* and at positions 86, 184, 1034, 1042, and 1246 in *P. falciparum multidrug resistance*-*1* (*pfmdr1*), which are suggested to be associated with resistance to a variety of anti-malarial drugs \[[@CR35]\], were determined by direct sequencing. An initial and nested PCR were performed with PrimeSTAR Max DNA Polymerase (Takara Bio Inc., Japan) in a 10-μL reaction mixture containing 1 μL of DNA template and 0.5 μM of each primer set. Excess primers and unincorporated nucleotides of the nested PCR product were enzymatically removed using ExoSAP-IT Kit (Amersham Biosciences, Buckinghamshire, UK) and direct sequencing was performed (96 °C or 1 min, 25 cycles of 96 °C for 30 s, 50 °C for 30 s, and 60 °C for 4 min, and 60 °C for 1 min) using a BigDye Terminator v1.1 cycle sequencing kit on the Applied Biosystems 3130/3130xl Genetic Analyzer (Life Technologies, Carlsbad, California, USA). Samples with minor peaks of at least 50% in height compared to the major peak were considered mixed genotypes.

Allele frequencies (proportion of parasite clones in the parasite population that carry a given allele) of drug-resistance genes were estimated using MalHaploFreq \[[@CR36]\], a program that utilizes allele prevalence and MOI data to estimate allele frequencies with a maximum likelihood algorithm using the maximum likelihood methodology.

Statistical analysis {#Sec8}
--------------------

All statistical analyses were performed using R software (Version 3.3.3). Data was analysed using Chi-square test, Fisher's exact test, Cochran--Armitage trend test, Jonckheere--Terpstrata test, and Welch's *t*-test. P-value \< 0.05 was considered significant.

Results {#Sec9}
=======

Enrolled patients {#Sec10}
-----------------

Among a total of 453 patients recruited, 60, 7 and 18 patients were diagnosed as *P. vivax* mono-infection, mixed infection with *P. falciparum* and *P. vivax*, and no malaria by using species-specific PCR and were removed from the enrolment. In total, 368 patients were enrolled for this study at two sampling clinics; 182 at Town clinic and 186 at Wirui Urban clinic. They are separated by about 2 km and nearly all background characteristics of enrolled patients were the same between the clinics (Additional file [1](#MOESM1){ref-type="media"}). The only difference was found in the frequency of pre-treated patients, which was significantly higher at Town clinic (11.5%) than that at Wirui clinic (3.2%) (*P *= 0.004, Chi-square test). The number of enrolled patients was similar for each year; 123 in 2016,134 in 2017, and 111 in 2018. Background characteristics of the enrolled patients did not significantly differ among the studied year.

Nearly 40% of the patients were 10 to 19 years old (Table [1](#Tab1){ref-type="table"}). No severe case was enrolled in the study. Median initial parasitaemia was 0.14%, 0.33%, and 0.12% in 2016, 2017, and 2018, respectively. In total, 27 enrolled patients presented a history of ingesting anti-malarial drug(s) within 2 weeks. Artemether alone (n = 12) and chloroquine (n = 10) were the two most used forms of self-medication. These patients were removed from further analysis, resulting in 341 patient samples.Table 1Characteristics of enrolled patientsCharacteristics2016 (N = 123)2017 (N = 134)2018 (N = 111)Sampling clinics; n (%) Wirui urban89 (72.4)40 (29.9)57 (51.4) Town34 (27.6)94 (70.1)54 (49.6)Age; n (%) 0--42 (1.6)5 (3.7)3 (2.7) 5--913 (10.6)19 (14.2)19 (17.1) 10--1943 (35)55 (41)44 (39.6) 20--2928 (22.8)32 (23.9)24 (21.6) 30--3915 (12.2)9 (6.7)8 (7.2) 40--4911 (8.9)6 (4.5)7 (6.3) 509 (7.3)7 (5.2)5 (4.5) Unknown2 (1.6)1 (0.7)1 (0.9) Average23.919.820.5Sex; n (%) Male53 (43.1)57 (42.5)57 (51.4) Female69 (56.1)76 (56.7)53 (47.7) Unknown1 (0.8)1 (0.8)1 (0.9)Pretreatment; n (%) Artemether3 (2.4)4 (3.0)5 (4.5) Artemether + lumefantrine0 (0)2 (1.5)1 (0.9) Artemether + lumefantrine + primaquine0 (0)1 (0.8)0 (0) Chloroquine2 (1.6)5 (3.7)3 (2.7) Primaquine1 (0.8)0 (0)0 (0)Parasitemia; (%) Median (IQR)0.14% (0.02%, 0.52%)0.33% (0.1%, 0.88%)0.12% (0.1%, 0.57%)MOI; n 198113ND 2139ND 310ND Mean1.131.07ND*IQR* interquartile range, *ND* not determined

Ex vivo susceptibility to chloroquine and lumefantrine {#Sec11}
------------------------------------------------------

Among the 341 patient samples, 113 were excluded from the ex vivo drug-susceptibility assay because of low (\< 0.05%) parasitaemia (n = 80) and lack of blood volume (n = 33); finally, blood samples from 228 patients were used in the ex vivo drug-susceptibility assay (62 in 2016, 101 in 2017, and 65 in 2018). Among these, interpretable ex vivo drug susceptibility data that fulfilled the criteria for core analysis \[[@CR37]\] were obtained in 174 assays for chloroquine. However, as high confidence on the estimated IC~50~ is tremendously important for this study, 36 results showing a ratio of high to low 95% confidence intervals for IC~50~ \> 2 were further excluded \[[@CR33]\]. This resulted in a total of 138 estimated IC~50~ values that almost completely fit with the inhibitory sigmoid Emax model (Table [2](#Tab2){ref-type="table"}). Average IC~50~ values to chloroquine were 106.6, 80.5, and 87.6 nM in 2016, 2017, and 2018, respectively. Although these values were slightly lower than those obtained in the previous study during 2002/2003 in the same study area (IC~50~ = 108 nM) \[[@CR24]\], these differences were not statistically significant. Accordingly, a decreasing trend was not found in the average IC~50~ values during 2016--2018 (Jonckheere--Terpstrata test).Table 2Ex vivo susceptibility of clinical parasites of *P. falciparum* in Papua New GuineaDrugNoMean IC50 (95% CI)201620172018Chloroquine138106.6 nM (79.4 nM, 133.9 nM)80.5 nM (68.6 nM, 92.3 nM)87.6 nM (72.6 nM, 102.5 nM)Lumefantrine74--4.6 (4.05 nM, 5.16 nM)--*CI* confidence intervals

Ex vivo drug susceptibility assay for lumefantrine was performed in 99 patients in 2017, producing 85 interpretable results. A total of 11 cases that showed a ratio of high to low 95% confidence intervals for IC~50~ \> 2 were further removed, which resulted in a total of 74 final results. The mean IC~50~ for lumefantrine was 4.6 nM.

Prevalence and frequencies of polymorphisms in *pfcrt* and *pfmdr1* {#Sec12}
-------------------------------------------------------------------

The prevalence of specific mutations in *pfcrt* and *pfmdr1* was determined (Additional file [2](#MOESM2){ref-type="media"}). Allele frequencies of *pfcrt* and *pfmdr1* were also estimated based on the prevalence of these alleles and Multiplicity of infections (MOIs) using MalHaploFreq \[[@CR36]\] (Table [3](#Tab3){ref-type="table"}). In 2018, because blood samples showing mixed alleles (ex, K76 + K76T in *pfcrt*) were not observed in both *pfcrt* and *pfmdr1*, allele frequencies were identical to allele prevalence and thus, MOIs were not determined in 2018. The maximum MOI detected was 3 and was observed in one sample (Table [1](#Tab1){ref-type="table"}). Mean MOIs in 2017 (1.07) were slightly lower than those in 2016 (1.13), both of which were similar or slightly lower than those previously observed in highland areas \[[@CR38]\].Table 3Allele frequencies in *pfcrt* and *pfmdr1*201620172018% CI^b^(%)% CI(%)%*Pfcrt* ^a^ CVMNK2.3 (0.5--6.1)10.4 (5.9--16.5)11.7 [S]{.ul}VMN[T]{.ul}97.7 (93.9--99.5)89.6 (83.5--94.1)88.3*Pfmdr1* N8658.7 (50--67.2)71.2 (63.2--78.5)73.3 N86Y41.3 (32.8--50)28.8 (21.5--36.8)26.7 Y18479.8 (72.2--86.3)71.2 (63.2--78.5)84.4 Y184F20.2 (13.7--27.8)28.8 (21.5--36.8)15.6 S1034100100100 S1034C000 N104292 (85--96.6)88.6 (81.4--93.9)89 N1042D8 (3.4--15)11.4 (6.1--18.6)11 D1246100100100 D1246Y000^a^Amino acids at positions 72--76, mutation underlined^b^95% confidential interval

Sequence analysis of codon 72--76 in *pfcrt* revealed two haplotypes, wild-type (CVMNK) and a mutant ([S]{.ul}VMN[T]{.ul}) (amino acids at positions 72--76, mutation underlined). The frequency of K76 depicted a significant upward trend: 2.3% in 2016, 10.4% in 2017, and 11.7% in 2018 (*P* = 0.008; Cochran--Armitage trend test). Similarly, a significant increase in the N86 allele in *pfmdr1* was observed: 58.7% in 2016, 71.2% in 2017, and 73.3% in 2018 (*P* = 0.006; Cochran--Armitage trend test). Meanwhile, no significant difference was found at position 184 and 1042 in *pfmdr1*. All isolates possessed a wild-type allele at position 1034 and 1246 in *pfmdr1*.

Association between ex vivo IC~50~ values for chloroquine and lumefantrine, and mutations in *pfcrt* and *pfmdr1* {#Sec13}
-----------------------------------------------------------------------------------------------------------------

Parasites harbouring the *pfcrt* K76T mutation depicted significantly higher IC~50~ values for chloroquine (97.1 nM) than those harbouring K76 (19.5 nM) (*P *= 2.2 × 10^−16^, Welch *t*-test) (Fig. [1](#Fig1){ref-type="fig"}). In *pfmdr1*, the N86Y mutation was significantly associated with lower IC~50~ values for lumefantrine (5.3 nM in N86Y vs. 10.9 nM in N86, *P* = 0.003, Welch *t*-test) (Fig. [2](#Fig2){ref-type="fig"}). Parasites harbouring a Y184F mutation showed significantly higher IC~50~ values for chloroquine (122.1 nM) than those with Y184 (80.7 nM) (*P* = 0.04, Welch *t*-test).Fig. 1Association between IC~50~ values for chloroquine and polymorphisms in *pfcrt* and *pfmdr1*. Statistical significance was calculated using Welch's *t*-test Fig. 2Association between IC~50~ values for lumefantrine and polymorphisms in *pfcrt* and *pfmdr1.* Statistical significance was calculated using Welch's *t*-test

To investigate the potential effect of Y184F in the augmentation of chloroquine resistance in K76T harbouring parasites, average IC~50~ values were compared between Y184 and Y184F in parasites with the *pfcrt* K76T mutation (Additional file [3](#MOESM3){ref-type="media"}). The Y184F harbouring parasites displayed significantly higher IC~50~ values (141.4 nM) than those of the Y184 harbouring parasites (90.2 nM) (*P *= 0.02, Welch *t*-test), suggesting that the Y184F mutation may augment the level of chloroquine resistance in *P. falciparum* parasites harbouring K76T in *pfcrt*.

Discussion {#Sec14}
==========

There are dozens of epidemiological studies showing that chloroquine-susceptible parasites replace resistant parasites in the absence of chloroquine selection \[[@CR7]--[@CR13]\]. However, the present analysis revealed a lack of substantial recovery of chloroquine susceptibility at 6--8 years after the withdrawal of chloroquine in Papua New Guinea.

In nearly all endemic regions where chloroquine-sensitive parasites re-emerged, reduction of parasites harbouring a K76T mutation in *pfcrt* played a pivotal role towards this phenomenon \[[@CR7]--[@CR10], [@CR12]\], though some exclusive regions have been reported, such as French Guiana \[[@CR39]\]. This is because the K76T mutation imposes some fitness cost to the parasites \[[@CR40]--[@CR43]\]. A reverse genetic study evidenced that introduction of K76T into chloroquine-susceptible clones induced a reduction in the growth rate \[[@CR41], [@CR42]\]. One suggested mechanism for this is that K76T harbouring parasites show functional impairment of haemoglobin digestion, which subsequently reduces the supply of amino acids required for parasite growth \[[@CR41]\]. Fitness reduction of chloroquine-resistant parasites was also reported in mosquito stages; K76T-bearing parasites were less selected than K76-bearing parasites in *Anopheles arabiensis* \[[@CR40]\]. Because of these disadvantages, K76T-harbouring parasites have been outcompeted by K76-harbouring parasites in the absence of chloroquine pressure \[[@CR4], [@CR6]\]. In this study, *pfcrt* K76T harbouring parasites showed a significantly higher IC~50~s than those in *pfcrt* K76 harbouring parasites. This observation is same as those observed in African endemic regions \[[@CR11], [@CR12]\], suggesting that an associated mechanism of chloroquine resistance would be common in parasites in Africa and Papua New Guinea. However, the majority of parasites still harboured the K76T allele and recovery of chloroquine susceptibility has not been observed even after withdrawal of chloroquine use. These observations suggest that genetic change(s) other than K76T in *pfcrt* and/or other unknown gene(s) compensate the fitness cost imposed by K76T and may explain the reason why chloroquine susceptibility is not returning at the same rate in Africa. It could be also possible to conjecture that, in Africa, there are some particular K76-harbouring parasites which have some stronger fitness advantage than K76-harbouring parasites in Papua New Guinea.

It has been suggested that amino acid differences flanking K76T affect the fitness disadvantage imposed by K76T \[[@CR42]\]. In the natural parasite population, there are two major mutant haplotypes constructed by five amino acids at positions 72--76: CV[IET]{.ul} and [S]{.ul}VMN[T]{.ul} \[[@CR42], [@CR44]\]. In Papua New Guinea, nearly all mutant parasites harboured a [S]{.ul}VMN[T]{.ul} haplotype, and the CV[IET]{.ul} haplotype was also observed with extremely low prevalence \[[@CR45], [@CR46]\]. A transfection study has reported that a [S]{.ul}VMN[T]{.ul} introduced isolate depicted lower growth rates than a wild-type (CVMNK) isolate, but better growth rate than the CV[IET]{.ul} introduced isolate \[[@CR42]\]. A quick repopulation of K76-harbouring parasites after chloroquine discontinuance has mostly been observed in the CV[IET]{.ul} haplotype regions. Therefore, the fact that all *pfcrt* mutants harboured a [S]{.ul}VMN[T]{.ul} haplotype may partly explain the persistent high prevalence of K76T in this study region.

However, it is striking that K76-harbouring parasites significantly increased during 2016--2018. This is the first study to show the potential repopulation of K76 harbouring parasites after chloroquine withdrawal in a [S]{.ul}VMN[T]{.ul} prevalent region. Despite a significant increase, the majority of parasites still harboured the K76T allele. Many environmental, population genetic, and parasitological factors potentially affect the rate of repopulation of susceptible parasites after chloroquine discontinuance \[[@CR5], [@CR47], [@CR48]\]. The frequency of susceptible parasites in the parasite population when chloroquine pressure was removed is one such important factor. Historically, the K76T allele had already become predominant or was nearly fixed by the late 1990s in many endemic regions in Papua New Guinea \[[@CR45], [@CR49]--[@CR51]\]. Accordingly, the K76T prevalence in our study region reached around 95% during 2002--2003 \[[@CR24]\]. Considering the strong selection pressure posed by the use of chloroquine for the treatment of uncomplicated malaria before 2010, an extremely low frequency of susceptible parasites is expected at the time when chloroquine was withdrawn. Therefore, it is considered that the observed high proportion of K76T harbouring parasites may be partly explained by the presumed extremely low initial proportion of K76-harbouring parasites.

A requirement for secondary determinants has been suggested for the augmentation of chloroquine resistance \[[@CR52]--[@CR54]\]. One such candidate gene is *pfmdr1* \[[@CR35], [@CR53]\]. In the present study, parasites with Y184F mutation displayed a significantly higher IC~50~ for chloroquine compared to those with Y184. This association was also found in parasites bearing *pfcrt*-K76T, suggesting that Y184F confers an additional factor for decreased chloroquine susceptibility in our study area. However, a previous reverse genetic study reported that an allele change from Y184 to Y184F conferred only a slight decrease in chloroquine susceptibility in a laboratory clone harbouring *pfcrt*-[S]{.ul}VMN[T]{.ul} \[[@CR55]\]. One possible explanation for this discrepancy is that genetic background could influence the role of the Y184F mutation on the augmentation of chloroquine resistance. The parasite clone used in the study by Veiga et al., was a KC5 clone, a progeny of the genetic cross between 7G8 (Brazil) and GB4 (Ghana) parasites \[[@CR56]\].

Persistence of chloroquine-selecting pressure potentially interferes the recovery of chloroquine-sensitive parasites. In Lagos, Nigeria where chloroquine was still widely used even after the introduction of ACT, *P. falciparum* parasites harbouring a K76T mutation continued to be highly prevalent \[[@CR57]\]. In Papua New Guinea, however, ACT has been used as a first-line treatment for all malaria species including *P. vivax*. Chloroquine has not been included in the official malaria-treatment regimen. However, although no stock of chloroquine in clinics and hospitals was confirmed in the studied area, chloroquine was still sold at two private pharmacies with a cheaper price than other anti-malarial drugs throughout the study period. Indeed, 2--4% of enrolled patients used chloroquine before visiting the clinics in this study. These observations indicate that chloroquine is still in use by some patients, which could play some role in a result of lack of complete withdrawal of chloroquine.

For lumefantrine, our average IC~50~ values (4.6 nM) were higher than those (1.5 nM) reported in Madang district during 2011--2013 \[[@CR23]\]. The N86 allele frequencies in our study (59--74%) were also much higher than those in the Madang study (\< 10%). In our study, a significant association was detected between higher IC~50~ values for lumefantrine and the N86 allele in *pfmdr1*. This is consistent with the previous transfection study in which an allelic change from N86Y to N86 resulted in a three to fourfold increase in the IC~50~ for lumefantrine \[[@CR55]\]. A recent meta-analysis has also shown that patients infected with parasites harbouring N86 had a fivefold risk of recrudescence in following artemether/lumefantrine treatment compared to those infected with parasites harbouring N86Y \[[@CR58]\]. The observed lower lumefantrine susceptibility and higher *pfmdr1*-N86 prevalence than that in the previous observation \[[@CR23]\] may raise the possibility of a decreasing trend of lumefantrine susceptibility in Papua New Guinea.

Conclusions {#Sec15}
===========

The present analysis provides molecular and ex vivo evidence for the absence of significant recovery of chloroquine susceptibility after 8 years of chloroquine withdrawal. On the other hand, this study also exhibits a significant increase in parasites harbouring K76 during the study period, albeit still in a small portion of the parasite population. It is well recognized that at the early phase when more fit strains are in a small portion, stochastic reasons rather than selective advantages play an important role in the increase of these strains \[[@CR59]\]. Once these strains reach a sufficiently large population, selective advantage considerably affects the expansion of these more fit strains \[[@CR59]\]. As such, current study hints at a reversal of chloroquine susceptibility in the future and warrants further continuous molecular epidemiological and phenotypic assessment of natural parasites in Papua New Guinea.
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